Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography-tandem mass spectrometry

Guodong Zhang, Alvin V Terry, Michael G. Bartlett

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

A simple, sensitive and robust liquid chromatography/electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) method with low matrix effects was developed and validated for the quantification of the lipophilic antipsychotic ziprasidone from rat plasma and brain tissue. Ziprasidone was extracted from rat plasma and brain homogenate using a single-step liquid-liquid extraction. Ziprasidone was separated on an Agilent Eclipse XDB C 8 column (150 × 2.1 mm i.d., 5 μm) column using a mobile phase of acetonitrile-0.02% ammonia in water (pH 7.20 adjusted with formic acid) using gradient elution. Ziprasidone was detected in the positive ion mode using multiple reaction monitoring. The method was validated and the specificity, linearity, lower limit of quantitation (LLOQ), precision, accuracy, recovery, matrix effects and stability were determined. The LLOQ was 0.2 ng/mL for plasma and 0.833 ng/g for brain tissue. The method was linear over the concentration range from 0.2 to 200.0 ng/mL for plasma and 0.833-833.3 ng/g for brain tissue. The correlation coefficient (R 2) values were more than 0.996 for both plasma and brain homogenate. The precision and accuracy intra-day and inter-day were better than 8.13%. The relative and absolute recovery was above 81.0% and matrix effects were lower than 52%. This validated method has been successfully used to quantify the rat plasma and brain tissue concentration of ziprasidone after chronic treatment.

Original languageEnglish (US)
Pages (from-to)770-778
Number of pages9
JournalBiomedical Chromatography
Volume22
Issue number7
DOIs
StatePublished - Jul 1 2008

Fingerprint

Liquid chromatography
Tandem Mass Spectrometry
Liquid Chromatography
Antipsychotic Agents
Mass spectrometry
Rats
Brain
Tissue
Plasmas
formic acid
Recovery
Electrospray ionization
Liquid-Liquid Extraction
Electrospray Ionization Mass Spectrometry
Liquids
Ammonia
ziprasidone
Positive ions
Ions
Water

Keywords

  • Brain tissue
  • LC-MS/MS
  • Matrix effect
  • Plasma
  • Ziprasidone

ASJC Scopus subject areas

  • Analytical Chemistry
  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography-tandem mass spectrometry. / Zhang, Guodong; Terry, Alvin V; Bartlett, Michael G.

In: Biomedical Chromatography, Vol. 22, No. 7, 01.07.2008, p. 770-778.

Research output: Contribution to journalArticle

@article{8fec2eef3689484889b9db90a854f516,
title = "Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography-tandem mass spectrometry",
abstract = "A simple, sensitive and robust liquid chromatography/electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) method with low matrix effects was developed and validated for the quantification of the lipophilic antipsychotic ziprasidone from rat plasma and brain tissue. Ziprasidone was extracted from rat plasma and brain homogenate using a single-step liquid-liquid extraction. Ziprasidone was separated on an Agilent Eclipse XDB C 8 column (150 × 2.1 mm i.d., 5 μm) column using a mobile phase of acetonitrile-0.02{\%} ammonia in water (pH 7.20 adjusted with formic acid) using gradient elution. Ziprasidone was detected in the positive ion mode using multiple reaction monitoring. The method was validated and the specificity, linearity, lower limit of quantitation (LLOQ), precision, accuracy, recovery, matrix effects and stability were determined. The LLOQ was 0.2 ng/mL for plasma and 0.833 ng/g for brain tissue. The method was linear over the concentration range from 0.2 to 200.0 ng/mL for plasma and 0.833-833.3 ng/g for brain tissue. The correlation coefficient (R 2) values were more than 0.996 for both plasma and brain homogenate. The precision and accuracy intra-day and inter-day were better than 8.13{\%}. The relative and absolute recovery was above 81.0{\%} and matrix effects were lower than 52{\%}. This validated method has been successfully used to quantify the rat plasma and brain tissue concentration of ziprasidone after chronic treatment.",
keywords = "Brain tissue, LC-MS/MS, Matrix effect, Plasma, Ziprasidone",
author = "Guodong Zhang and Terry, {Alvin V} and Bartlett, {Michael G.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1002/bmc.999",
language = "English (US)",
volume = "22",
pages = "770--778",
journal = "Biomedical Chromatography",
issn = "0269-3879",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography-tandem mass spectrometry

AU - Zhang, Guodong

AU - Terry, Alvin V

AU - Bartlett, Michael G.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - A simple, sensitive and robust liquid chromatography/electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) method with low matrix effects was developed and validated for the quantification of the lipophilic antipsychotic ziprasidone from rat plasma and brain tissue. Ziprasidone was extracted from rat plasma and brain homogenate using a single-step liquid-liquid extraction. Ziprasidone was separated on an Agilent Eclipse XDB C 8 column (150 × 2.1 mm i.d., 5 μm) column using a mobile phase of acetonitrile-0.02% ammonia in water (pH 7.20 adjusted with formic acid) using gradient elution. Ziprasidone was detected in the positive ion mode using multiple reaction monitoring. The method was validated and the specificity, linearity, lower limit of quantitation (LLOQ), precision, accuracy, recovery, matrix effects and stability were determined. The LLOQ was 0.2 ng/mL for plasma and 0.833 ng/g for brain tissue. The method was linear over the concentration range from 0.2 to 200.0 ng/mL for plasma and 0.833-833.3 ng/g for brain tissue. The correlation coefficient (R 2) values were more than 0.996 for both plasma and brain homogenate. The precision and accuracy intra-day and inter-day were better than 8.13%. The relative and absolute recovery was above 81.0% and matrix effects were lower than 52%. This validated method has been successfully used to quantify the rat plasma and brain tissue concentration of ziprasidone after chronic treatment.

AB - A simple, sensitive and robust liquid chromatography/electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) method with low matrix effects was developed and validated for the quantification of the lipophilic antipsychotic ziprasidone from rat plasma and brain tissue. Ziprasidone was extracted from rat plasma and brain homogenate using a single-step liquid-liquid extraction. Ziprasidone was separated on an Agilent Eclipse XDB C 8 column (150 × 2.1 mm i.d., 5 μm) column using a mobile phase of acetonitrile-0.02% ammonia in water (pH 7.20 adjusted with formic acid) using gradient elution. Ziprasidone was detected in the positive ion mode using multiple reaction monitoring. The method was validated and the specificity, linearity, lower limit of quantitation (LLOQ), precision, accuracy, recovery, matrix effects and stability were determined. The LLOQ was 0.2 ng/mL for plasma and 0.833 ng/g for brain tissue. The method was linear over the concentration range from 0.2 to 200.0 ng/mL for plasma and 0.833-833.3 ng/g for brain tissue. The correlation coefficient (R 2) values were more than 0.996 for both plasma and brain homogenate. The precision and accuracy intra-day and inter-day were better than 8.13%. The relative and absolute recovery was above 81.0% and matrix effects were lower than 52%. This validated method has been successfully used to quantify the rat plasma and brain tissue concentration of ziprasidone after chronic treatment.

KW - Brain tissue

KW - LC-MS/MS

KW - Matrix effect

KW - Plasma

KW - Ziprasidone

UR - http://www.scopus.com/inward/record.url?scp=48349124047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48349124047&partnerID=8YFLogxK

U2 - 10.1002/bmc.999

DO - 10.1002/bmc.999

M3 - Article

VL - 22

SP - 770

EP - 778

JO - Biomedical Chromatography

JF - Biomedical Chromatography

SN - 0269-3879

IS - 7

ER -